Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor (Celebrex/Celecoxib) maybe a potential alternative strategy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University Hospital
• Collaborator: Ministry of Health and Welfare, Taiwan
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

1. OSCC patients with T1,2/ N0 and without pathological risk features

2. OSCC patients with T1,2/ N0,1 and pathological risk features

3. OSCC patients with T4a/ N2,3

Exclusion Criteria:

1. Pregnant women paitents

2. Taiwanese aboriginal patients

3. Not primary OSCC patients

4. OSCC patients with dysfunction of liver and/or kidneys